Core Viewpoint - 康沣生物-B (06922) reported significant revenue growth and a reduction in losses for the first half of 2025, driven by increased sales of respiratory intervention products following regulatory approvals [1] Financial Performance - Revenue reached 51.106 million yuan, representing a year-on-year increase of approximately 162% [1] - Gross profit amounted to 34.312 million yuan, reflecting a year-on-year growth of about 125% [1] - Loss attributable to shareholders narrowed to 23.817 million yuan, a reduction of 54.35% compared to the previous year [1] - Earnings per share reported a loss of 0.1 yuan [1] Product and Market Development - Revenue growth was primarily driven by the sales increase of the malignant stenosis cryoablation system and cryoadhesion treatment system, which received approval from the National Medical Products Administration in March 2025 [1] - Additionally, sales of other respiratory intervention products by 波科国际医疗贸易 (Shanghai) Co., Ltd. also increased during the reporting period [1] Strategic Initiatives - The reduction in losses is attributed to the company's optimized development strategy and effective measures implemented for group cost control [1]

Core Viewpoint - 康沣生物-B (06922) reported a significant increase in revenue and a reduction in losses for the first half of 2025, driven by the sales of newly approved respiratory intervention products [1] Financial Performance - Revenue reached 51.106 million yuan, representing a year-on-year increase of approximately 162% [1] - Gross profit amounted to 34.312 million yuan, reflecting a year-on-year growth of about 125% [1] - Loss attributable to the parent company narrowed to 23.817 million yuan, a reduction of 54.35% compared to the previous year [1] - Earnings per share reported a loss of 0.1 yuan [1] Product and Market Development - Revenue growth was primarily driven by the sales increase of the malignant stenosis cryoablation system and cryoadhesion treatment system, which received approval from the National Medical Products Administration in March 2025 [1] - Additionally, sales of other respiratory intervention products distributed by 波科国际医疗贸易 (Shanghai) Co., Ltd. also increased during the reporting period [1] Strategic Initiatives - The reduction in losses is attributed to the company's optimized development strategy and effective measures implemented for group cost control [1]

Core Viewpoint - 康沣生物-B (06922.HK) reported significant revenue growth and reduced losses for the six months ending June 30, 2025, driven by increased sales of respiratory intervention products following regulatory approval [1] Financial Performance - Revenue increased to RMB 51.1 million, representing a year-on-year growth of 162.4% [1] - Losses decreased from RMB 56.0 million for the six months ending June 30, 2024, to RMB 27.2 million for the same period in 2025, a reduction of RMB 28.8 million or 51.4% [1] Product Development - The revenue growth was primarily attributed to the sales increase of the malignant stenosis cryoablation system and cryoadhesion treatment system, which received approval from the National Medical Products Administration in March 2025 [1] - Additionally, sales of other respiratory intervention products distributed by 波科国际医疗贸易 (Shanghai) Co., Ltd. also contributed to the revenue increase during the reporting period [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 Cryofocus Medtech (Shanghai) Co., Ltd. 截至2025年6月30日止六個月的中期業績公告 財務摘要 截至6月30日止六個月 2025年 2024年 （未經審核） （未經審核） 人民幣千元 人民幣千元 收入 51,106 19,475 毛利 34,312 15,281 研發開支 (17,907) (37,222) 期內虧損 (27,221) (55,953) 業務摘要 於報告期間及截至本公告日期，我們在產品管線及業務營運方面取得多項進 展，包括但不限於： • 我們的收入由截至2024年6月30日止六個月的的人民幣19.5百萬元增加至截 至2025年6月30日止六個月的人民幣51.1百萬元，增加人民幣31.6百萬元， 增幅為162.4%，主要受於2025年3月獲國家藥監局批准的惡性狹窄冷凍消 融系統及冷凍粘連治療系統等呼吸介入產品的銷量增加所帶動。此外，波 科國際醫療貿易（ ...

Group 1 - The article provides a list of companies involved in various financial activities such as earnings announcements, shareholder meetings, and new stock activities [2][3] - Several companies are mentioned for their dividend distribution dates, indicating their financial performance and shareholder returns [2][3] - The document highlights companies undergoing stock repurchases and capital increases, which may signal their financial strategies and market positioning [3] Group 2 - The article includes a list of companies that are currently in the process of IPOs, reflecting market interest and potential investment opportunities [2] - Companies like Silver Noble Pharmaceuticals and others are noted for their ongoing stock activities, which may attract investor attention [2] - The document also mentions companies that are resuming trading, indicating a potential recovery or change in market conditions [2]

Core Viewpoint - 康沣生物-B (06922) has received regulatory approvals for its cryoadhesion treatment system and its disposable cryoprobes, enhancing its commercialization pathway for respiratory intervention products [1] Group 1: Regulatory Approvals - The disposable cryoprobes received approval from the National Medical Products Administration (NMPA) on January 9, 2024 [1] - The registration change for the cryoprobes was granted by the NMPA on August 5, 2025 [1] Group 2: Product Features and Applications - The cryoadhesion treatment system utilizes subcritical cooling technology and controlled pressure heat transfer technology for rapid freezing adhesion [1] - The system is designed for the removal of foreign bodies, mucus, blood clots, and necrotic tissue in the airway, as well as for cryobiopsy of bronchial and lung tissues [1]

Group 1 - The company 康沣生物-B (06922) has received regulatory approval from the National Medical Products Administration (NMPA) for its disposable cryoprobes on January 9, 2024, enhancing its commercial pathway for the cryoadhesion treatment system [1] - The registration change for the disposable cryoprobes to cryoprobes was approved by the NMPA on August 5, 2025, indicating a significant step in product development [1] - The cryoadhesion treatment system utilizes subcritical refrigeration technology and controlled pressure heat transfer technology for rapid freezing adhesion, aimed at removing foreign bodies, mucus, blood clots, and necrotic tissue in the airway, as well as for cryobiopsy of bronchial and lung tissues [1]

在获得国家药监局授出的该等批文后，集团的冷冻粘连治疗系统商业化路径将更加完善，冷冻探头将以 一次性及重复使用的产品特性对相关适应症进行全面覆盖。 格隆汇8月7日丨康沣生物-B(06922.HK)发布公告，继集团的冷冻粘连治疗系统，集团的呼吸介入产品之 一，的其他部件（即一次性使用冷冻探头）于2024年1月9日获得国家药品监督管理局授出的批文后，一 次性使用冷冻探头注册变更为冷冻探头已于2025年8月5日获得国家药监局授出的批文。 冷冻粘连治疗系统采用亚临界制冷技术及控压传热技术进行快速冷冻粘连，将用于气道内异物、黏液、 血液凝块和坏死组织的冷冻去除以及支气管和肺部组织的冷冻活检。 ...

康灃生物科技（上海）股份有限公司 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 Cryofocus Medtech (Shanghai) Co., Ltd. 冷凍粘連治療系統的一次性使用冷凍探頭變更註冊獲得國家藥監局批文 本公告乃由康灃生物科技（上海）股份有限公司（「本公司」，連同其附屬公司統稱 為「本集團」）自願作出，以告知本公司股東及潛在投資者有關本集團業務的最新 進展。 本公司欣然宣佈，繼本集團的冷凍粘連治療系統（「冷凍粘連治療系統」），本集團 的呼吸介入產品之一，的其他部件（即一次性使用冷凍探頭）於2024年1月9日獲得 國家藥品監督管理局（「國家藥監局」）授出的批文後，一次性使用冷凍探頭註冊變 更為冷凍探頭已於2025年8月5日獲得國家藥監局授出的批文。 在獲得國家藥監局授出的該等批文後，本集團的冷凍粘連治療系統商業化路徑將 更加完善，冷凍探頭將以一次性及重複使用的產品特性對相關適應症進行全面覆 蓋。 冷凍粘連治療系統採用亞臨界製冷技術及控 ...

格隆汇7月29日丨康沣生物-B(06922.HK)发布公告，谨定于2025年8月8日（星期五）召开董事会会议， 以（其中包括）审议及通过集团截至2025年6月30日止六个月的中期业绩及其发布，以及审议派发中期 股息的建议（如有）。 ...